Intercept Pharmaceuticals (ICPT)

Intercept Pharmaceuticals, Inc. (ICPT) CEO Jerry Durso on Q1 2022 Results - Earnings Call Transcrip
May 6, 2022 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals, Inc. (ICPT) CEO Jerry Durso on Q4 2021 Results - Earnings Call Transcrip
March 2, 2022 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals, inc (ICPT) Q3 2021 Earnings Call Transcript
Nov. 3, 2021 | Price: Free! | Source: Motley Fool

Intercept Pharmaceuticals, inc (ICPT) Q2 2021 Earnings Call Transcript
July 30, 2021 | Price: Free! | Source: Motley Fool

Intercept Pharmaceuticals, Inc. (ICPT) CEO Jerry Durso on Q2 2021 Results - Earnings Call Transcrip
July 29, 2021 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals' (ICPT) CEO Jerry Durso on Q1 2021 Results - Earnings Call Transcript
May 6, 2021 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals Inc (ICPT) Q1 2021 Earnings Call Transcript
May 6, 2021 | Price: Free! | Source: Motley Fool

Intercept Pharmaceuticals, Inc. (ICPT) CEO Jerry Durso on Q4 2020 Results - Earnings Call Transcrip
Feb. 25, 2021 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals Inc (ICPT) Q4 2020 Earnings Call Transcript
Feb. 25, 2021 | Price: Free! | Source: Motley Fool

Intercept Pharmaceuticals, Inc. (ICPT) CEO Mark Pruzanski on Q3 2020 Results - Earnings Call Transc
Nov. 9, 2020 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals Inc (ICPT) Q3 2020 Earnings Call Transcript
Nov. 9, 2020 | Price: Free! | Source: Motley Fool

Intercept Pharmaceuticals Inc (ICPT) Q2 2020 Earnings Call Transcript
Aug. 10, 2020 | Price: Free! | Source: Motley Fool

Intercept Pharmaceuticals (ICPT) Q2 2020 Results - Earnings Call Transcript
Aug. 10, 2020 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals Inc (ICPT) Q1 2020 Earnings Call Transcript
May 11, 2020 | Price: Free! | Source: Motley Fool

Intercept Pharmaceuticals, Inc. (ICPT) CEO Mark Pruzanski on Q1 2020 Results - Earnings Call Transc
May 11, 2020 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals Inc (ICPT) Q4 2019 Earnings Call Transcript
Feb. 25, 2020 | Price: Free! | Source: Motley Fool

Intercept Pharmaceuticals, Inc. (ICPT) CEO Mark Pruzanski on Q4 2019 Results - Earnings Call Transc
Feb. 25, 2020 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals Inc (ICPT) Q3 2019 Earnings Call Transcript
Nov. 5, 2019 | Price: Free! | Source: Motley Fool

Intercept Pharmaceuticals, Inc. (ICPT) CEO Mark Pruzanski on Q3 2019 Results - Earnings Call Transc
Nov. 5, 2019 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals Inc (ICPT) Q2 2019 Earnings Call Transcript
Aug. 7, 2019 | Price: Free! | Source: Motley Fool

Intercept Pharmaceuticals, Inc. (ICPT) CEO Mark Pruzanski on Q2 2019 Results - Earnings Call Transc
Aug. 7, 2019 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals, Inc. (ICPT) CEO Mark Pruzanski on Q1 2019 Results - Earnings Call Transc
May 8, 2019 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals, Inc. (ICPT) CEO Dr. Mark Pruzanski on Q4 2018 Results - Earnings Call Tr
Feb. 28, 2019 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals (ICPT) Q3 2018 Results - Earnings Call Transcript
Oct. 31, 2018 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals (ICPT) Q1 2018 Results - Earnings Call Transcript
May 8, 2018 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals (ICPT) CEO Mark Pruzanski on Q4 2017 Results - Earnings Call Transcript
Feb. 14, 2018 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals (ICPT) Q3 2017 Results - Earnings Call Transcript
Nov. 1, 2017 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals' (ICPT) CEO Mark Pruzanski Presents at Morgan Stanley 15th Annual Global
Sept. 12, 2017 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals (ICPT) Q2 2017 Results - Earnings Call Transcript
July 31, 2017 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals (ICPT) Q1 2017 Results - Earnings Call Transcript
May 4, 2017 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals (ICPT) Q4 2016 Results - Earnings Call Transcript
Feb. 23, 2017 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals' (ICPT) CEO Mark Pruzanski on Q3 2016 Results - Earnings Call Transcript
Nov. 3, 2016 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals (ICPT) Mark E. Pruzanski on Q2 2016 Results - Earnings Call Transcript
Aug. 4, 2016 | Price: Free! | Source: Seeking Alpha

INTERCEPT PHARMA INC (ICPT) Earnings Report: Q1 2016 Conference Call Transcript
May 9, 2016 | Price: Free! | Source: The Street

Intercept Pharmaceuticals (ICPT) Mark E. Pruzanski on Q1 2016 Results - Earnings Call Transcript
May 6, 2016 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals (ICPT) Mark E. Pruzanski on Q4 2015 Results - Earnings Call Transcript
Feb. 23, 2016 | Price: Free! | Source: Seeking Alpha

Intercept Pharma (ICPT) Earnings Report: Q4 2015 Conference Call Transcript
Feb. 23, 2016 | Price: Free! | Source: The Street

Intercept Pharmaceuticals (ICPT) Earnings Report: Q3 2015 Conference Call Transcript
Nov. 12, 2015 | Price: Free! | Source: The Street

Intercept Pharmaceuticals (ICPT) Mark E. Pruzanski on Q3 2015 Results - Earnings Call Transcript
Nov. 9, 2015 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals (ICPT) Earnings Report: Q2 2015 Conference Call Transcript
Aug. 6, 2015 | Price: Free! | Source: The Street

Intercept Pharmaceuticals (ICPT) Mark E. Pruzanski on Q2 2015 Results - Earnings Call Transcript
Aug. 5, 2015 | Price: Free! | Source: Seeking Alpha

Intercept Pharma (ICPT) Earnings Report: Q1 2015 Conference Call Transcript
May 11, 2015 | Price: Free! | Source: The Street

Intercept Pharmaceuticals' (ICPT) CEO Mark Pruzanski on Q1 2015 Results - Earnings Call Transcript
May 11, 2015 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals (ICPT) Investor Meeting at AASLD Colloquium (Transcript)
March 23, 2015 | Price: Free! | Source: Seeking Alpha

Intercept Pharma (ICPT) Earnings Report: Q4 2014 Conference Call Transcript
March 2, 2015 | Price: Free! | Source: The Street

Intercept Pharmaceuticals' (ICPT) CEO Dr. Mark Pruzanski Discusses Q4 2014 Results - Earnings Call
March 2, 2015 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals' (ICPT) AASLD Investor Event - Transcript
Nov. 11, 2014 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals' (ICPT) CEO Dr. Mark Pruzanski on Q2 2014 Results - Earnings Call Transcr
Aug. 11, 2014 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals' (ICPT) CEO Mark Pruzanski on Q1 2014 Results - Earnings Call Transcript
May 7, 2014 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals' CEO Discusses Q4 2013 Results - Earnings Call Transcript
March 17, 2014 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals, Inc. - Business Update Call Transcript
Jan. 9, 2014 | Price: Free! | Source: Earnings Impact

Intercept's CEO Discusses 2013 Year-End Update on Clinical Programs (Transcript)
Jan. 9, 2014 | Price: Free! | Source: Seeking Alpha

Intercept Pharmaceuticals, Inc. - Wedbush 2013 Life Sciences Management Access Conference Transcrip
Aug. 13, 2013 | Price: Free! | Source: Earnings Impact

Intercept Pharmaceuticals, Inc. - JMP Securities 8th Annual Healthcare Conference Transcript
July 9, 2013 | Price: Free! | Source: Earnings Impact

Intercept's CEO Discusses Q4 2012 Results - Earnings Call Transcript
March 18, 2013 | Price: Free! | Source: Seeking Alpha

Recent filings

Submission of Matters to a Vote of Security - May 25, 2022

Intercept Pharmaceuticals's EVP & Chief Commercial Officer just disposed of 124 shares - May 17, 2022

Intercept: Soliciting Material Pursuant To §240.14A-12 Intercept Pharmaceuticals, Inc. - May 13, 2022

Intercept Pharmaceuticals Just Filed Its Quarterly Report: 13.   Net Loss Per ... - May 6, 2022

Intercept Pharmaceuticals Reports First Quarter 2022 Financial Results And Provides Business Update - May 6, 2022

Intercept Announces Advanz Pharma To Acquire Ocaliva In Pbc In Markets Outside The U.S. For Up To $450Mm, Including $405Mm Upfront And An Additional $45Mm In Contingent Payments - May 5, 2022

Intercept Pharmaceuticals's General Counsel just disposed of 771 shares - May 3, 2022

Intercept Pharmaceuticals releases salary data. CEO received compensation of $Mr. Jerome Durso becam - May 2, 2022

Intercept Pharmaceuticals's Chief Qual. Officer & SVP Ops. just disposed of 531 shares - April 13, 2022

Intercept Pharmaceuticals Just Filed Its Annual Report: Net Loss Per ShareBa... - March 2, 2022

Intercept Pharmaceuticals Reports Fourth Quarter And Full Year 2021 Financial Results, Issues 2022 Financial Guidance And Provides Business Update - March 2, 2022

Intercept Pharmaceuticals's EVP & Chief Commercial Officer just disposed of 171 shares - Feb. 17, 2022

SVP of Intercept Pharmaceuticals just disposed of 320 shares - Feb. 15, 2022

Intercept Pharmaceuticals's EVP & Chief Commercial Officer just disposed of 529 shares - Feb. 15, 2022

Statement of acquisition of beneficial ownership by individuals - Feb. 11, 2022

The Vanguard Group just provided an update on share ownership of Intercept Pharmaceuticals - Feb. 10, 2022

Entry into a Material Definitive - Feb. 9, 2022

Statement of acquisition of beneficial ownership by individuals - Feb. 9, 2022

On February - Feb. 7, 2022

On February - Feb. 7, 2022

Intercept Pharmaceuticals's General Counsel just disposed of 4,072 shares - Feb. 3, 2022

BlackRock, Inc. just provided an update on share ownership of Intercept Pharmaceuticals - Feb. 3, 2022

First Trust Portfolios L.P. just issued a filing suggesting it has sold all of its Intercept Pharmaceuticals - Feb. 2, 2022

Intercept Pharmaceuticals's Chief Accounting Officer just picked up 3,600 shares - Jan. 31, 2022

On January - Jan. 31, 2022

Intercept Pharmaceuticals's Chief Qual. Officer & SVP Ops. just picked up 3,600 shares - Jan. 31, 2022

President of Intercept Pharmaceuticals just picked up 10,300 shares - Jan. 31, 2022

Intercept Pharmaceuticals's Chief Human Resources Officer just picked up 6,600 shares - Jan. 31, 2022

Intercept Pharmaceuticals's President & CEO just picked up 35,700 shares - Jan. 31, 2022

SVP of Intercept Pharmaceuticals just picked up 6,600 shares - Jan. 31, 2022

Intercept Pharmaceuticals's EVP & Chief Commercial Officer just picked up 10,300 shares - Jan. 31, 2022

Intercept Pharmaceuticals's General Counsel just picked up 10,300 shares - Jan. 31, 2022

Intercept Pharmaceuticals's EVP & Chief Financial Officer just picked up 10,300 shares - Jan. 31, 2022

Intercept Pharmaceuticals's Chief Qual. Officer & SVP Ops. just disposed of 2,455 shares - Jan. 13, 2022

Departure of Directors or Certain - Jan. 10, 2022

Intercept Pharmaceuticals's Chief Human Resources Officer just disposed of 1,712 shares - Jan. 4, 2022

SVP of Intercept Pharmaceuticals just disposed of 542 shares - Jan. 4, 2022

SVP of Intercept Pharmaceuticals just disposed of 2,455 shares - Jan. 4, 2022

Intercept Pharmaceuticals's President & CEO just disposed of 5,941 shares - Jan. 4, 2022

Statement of changes in beneficial ownership of securities - Jan. 4, 2022

Intercept Pharmaceuticals's Chief Accounting Officer just disposed of 550 shares - Jan. 4, 2022

Intercept Pharmaceuticals Provides Update On Phase 3 Reverse Trial In Compensated Cirrhosis Due To Nash - Dec. 20, 2021

Statement of acquisition of beneficial ownership by individuals - Dec. 10, 2021

Intercept Announces Withdrawal Of Ema Marketing Authorization Application For Obeticholic Acid For Advanced Liver Fibrosis Due To Nash - Dec. 9, 2021

Intercept Pharmaceuticals director just picked up 2,321 shares - Dec. 2, 2021

Intercept Pharmaceuticals's EVP & Chief Commercial Officer just disposed of 171 shares - Nov. 17, 2021

SVP of Intercept Pharmaceuticals just disposed of 319 shares - Nov. 16, 2021

Intercept Pharmaceuticals Reports Third Quarter 2021 Financial Results And Provides Business Update - Nov. 3, 2021

Intercept Pharmaceuticals Just Filed Its Quarterly Report: 16.   Net Loss Per ... - Nov. 3, 2021

Intercept Pharmaceuticals director just picked up 2,321 shares - Nov. 2, 2021

Submission of Matters to a Vote of Security - Oct. 22, 2021

Intercept Pharmaceuticals's Chief Human Resources Officer just disposed of 92 shares - Oct. 5, 2021

Intercept Pharmaceuticals's Chief Accounting Officer just disposed of 30 shares - Oct. 5, 2021

Intercept Pharmaceuticals's President & CEO just disposed of 289 shares - Oct. 5, 2021

SVP of Intercept Pharmaceuticals just disposed of 204 shares - Oct. 4, 2021

Intercept Pharmaceuticals director just picked up 2,320 shares - Oct. 4, 2021

Securities to be offered to employees in employee benefit plans - Sept. 29, 2021

Tender offer statement by Issuer - Sept. 21, 2021

Tender offer statement by Issuer - Sept. 16, 2021

Tender offer statement by Issuer - Sept. 9, 2021

SVP of Intercept Pharmaceuticals just disposed of 538 shares - Sept. 3, 2021

Statement of changes in beneficial ownership of securities - Sept. 3, 2021

Intercept Pharmaceuticals's Chief Accounting Officer just disposed of 524 shares - Sept. 3, 2021

Intercept Pharmaceuticals director just picked up 2,321 shares - Sept. 1, 2021

Tender offer statement by Issuer - Sept. 1, 2021

Entry into a Material Definitive - Aug. 23, 2021

Intercept Pharmaceuticals's EVP & Chief Commercial Officer just disposed of 171 shares - Aug. 16, 2021

SVP of Intercept Pharmaceuticals just disposed of 319 shares - Aug. 13, 2021

Intercept Pharmaceuticals Announces Convertible Notes Exchange, New Issuance And Stock Repurchase - Aug. 11, 2021

Intercept Pharmaceuticals director just picked up 2,321 shares - Aug. 2, 2021

Intercept Pharmaceuticals Just Filed Its Quarterly Report: 15.   Net Loss Per ... - July 29, 2021

Intercept Pharmaceuticals Reports Second Quarter 2021 Financial Results And Provides Business Update - July 29, 2021

Written communication relating to an issuer or third party - July 19, 2021

Intercept Pharmaceuticals's Chief Human Resources Officer just disposed of 92 shares - July 2, 2021

Intercept Pharmaceuticals's President & CEO just disposed of 289 shares - July 2, 2021

Intercept Pharmaceuticals's Chief Accounting Officer just disposed of 30 shares - July 2, 2021

Statement of changes in beneficial ownership of securities - July 1, 2021

Written communication relating to an issuer or third party - July 1, 2021

Intercept Pharmaceuticals's EVP & Chief Financial Officer just picked up 52,156 shares - June 22, 2021

Initial statement of beneficial ownership of securities - June 22, 2021

President of Intercept Pharmaceuticals just declared ownership of no shares of Intercept Pharmaceuticals - June 15, 2021

President of Intercept Pharmaceuticals just picked up 67,118 shares - June 15, 2021

Statement of acquisition of beneficial ownership by individuals - June 10, 2021

Intercept Appoints Andrew Saik As Chief Financial Officer - June 7, 2021

Statement of changes in beneficial ownership of securities - June 2, 2021

Statement of changes in beneficial ownership of securities - June 1, 2021

Intercept Pharmaceuticals director just picked up 10,543 shares - June 1, 2021

Major owner of Intercept Pharmaceuticals just picked up 7,029 shares - June 1, 2021

Intercept Pharmaceuticals director just picked up 7,029 shares - June 1, 2021

Intercept Pharmaceuticals director just picked up 7,029 shares - June 1, 2021

Intercept Pharmaceuticals director just picked up 7,029 shares - June 1, 2021

Intercept Pharmaceuticals director just picked up 7,029 shares - June 1, 2021

Intercept Pharmaceuticals director just picked up 7,029 shares - June 1, 2021

Statement of changes in beneficial ownership of securities - June 1, 2021

Current report, items 5.02 and 5.07 - May 27, 2021

Intercept Announces Updated Ocaliva® (Obeticholic Acid) U.S. Prescribing Information - May 26, 2021

Intercept Pharmaceuticals's EVP & Chief Commercial Officer just disposed of 171 shares - May 17, 2021

SVP of Intercept Pharmaceuticals just disposed of 319 shares - May 13, 2021

Intercept Pharmaceuticals's Chief Human Resources Officer just disposed of 128 shares - May 11, 2021

Current report, items 2.02 and 9.01 - May 6, 2021

Sorry, no schedule available for this company

Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results, Issues 2022 Financial Guidance and Provides Business Update - March 2, 2022

Intercept to Announce Fourth Quarter and Full Year 2021 Financial Results on March 2, 2022 - Feb. 23, 2022

Pomerantz Law Firm Announces the Filing of a Class Action against Intercept Pharmaceuticals, Inc. and Certain Officers - ICPT - Jan. 6, 2022

Intercept Pharmaceuticals Provides Update on Phase 3 REVERSE Trial in Compensated Cirrhosis Due to NASH - Dec. 20, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intercept Pharmaceuticals, Inc. - ICPT - Dec. 13, 2021

Intercept Announces Withdrawal of EMA Marketing Authorization Application for Obeticholic Acid for Advanced Liver Fibrosis Due to NASH - Dec. 9, 2021

Intercept Announces New Long-Term Data Demonstrating Potential of Obeticholic Acid to Improve Transplant-Free Survival in Patients with PBC - Nov. 15, 2021

Intercept to Present at Upcoming Investor Conferences - Nov. 11, 2021

Intercept Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update - Nov. 3, 2021

Intercept Announces Late-Breaking Oral Presentation and Poster Presentations at The Liver Meeting - Nov. 2, 2021

Intercept to Present at the 2021 Cantor Virtual Global Healthcare Conference - Sept. 21, 2021

Intercept to Present at the Virtual Baird 2021 Global Healthcare Conference - Sept. 1, 2021

Intercept Pharmaceuticals Announces Convertible Notes Exchange, New Issuance and Stock Repurchase - Aug. 10, 2021

Intercept to Announce Second Quarter 2021 Financial Results on July 29, 2021 - July 19, 2021

Intercept to Present at the Raymond James 2021 Human Health Innovation Conference - June 15, 2021

Intercept Appoints M. Michelle Berrey, M.D., M.P.H., as President of Research & Development and Chief Medical Officer - June 9, 2021

Intercept Announces Updated Ocaliva® (obeticholic acid) U.S. Prescribing Information - May 26, 2021

Intercept to Present at the 2021 RBC Capital Markets Global Healthcare Conference - May 12, 2021

Intercept Announces Departure of Chief Financial Officer - March 10, 2021

Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results, Issues 2021 Financial Guidance and Provides Business Update - Feb. 25, 2021

 


Feedback